Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - MyoKardia, Inc. | d214197dex992.htm |
| EX-99.1 - EX-99.1 - MyoKardia, Inc. | d214197dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 11, 2016
MYOKARDIA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37609 | 44-5500552 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
333 Allerton Ave.
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 741-0900
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On July 11, 2016, MyoKardia, Inc. (the “Company”) issued a press release titled, “MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients” (the “Press Release”) and made available on the Company’s website a supplemental slide presentation regarding certain information in the Press Release (the “Presentation”). Copies of the Press Release and the Presentation are filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press Release dated July 11, 2016 | |
| 99.2 | Data Supplement to Press Release dated July 11, 2016 (slide presentation) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 11, 2016 | MyoKardia, Inc. | |||
| By: | /s/ Steven Chan | |||
| Steven Chan | ||||
| Vice President, Corporate Controller (principal financial and accounting officer) | ||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release dated July 11, 2016 | |
| 99.2 | Data Supplement to Press Release dated July 11, 2016 (slide presentation) | |